Côté J F, Klijanienko J, Meunier M, Zafrani B, Thibault F, Clough K, Asselain B, Vielh P
Département de Pathologie, Institut Curie, Paris, France.
Cancer. 1998 Apr 25;84(2):77-83.
The early diagnosis of nonpalpable breast lesions is a medical challenge because of the low specificity of different radiologic modalities. Fine-needle aspiration cytology (FNAC) assisted by a stereotactic guidance is an adjunctive diagnostic approach in the management of these lesions. The primary purpose of this article was to assess the diagnostic accuracy of FNAC in patients with nonpalpable breast lesions.
Three hundred and seventy-one lesions from 357 patients (all female) underwent FNAC using the stereotactically guided technique. Of these cases, 243 lesions from 238 patients subsequently were acquired by surgical excisional biopsies and formed the basis of this study. Statistical analyses of the cytologic and the histologic diagnoses of these cases were performed.
Histologically, 107 lesions (44%) were benign and 136 lesions (56%) were malignant. Of the 136 malignant lesions, cytology was concordant in 73 lesions (53.7%), suspicious in 15 lesions (11.0%), false-negative in 12 lesions (8.8%) (benign), and unsatisfactory in 36 lesions (26.5%). Among the 107 benign lesions, cytology was concordant with histology in 75 lesions (70.1%), whereas 4 lesions (3.7%) and 28 lesions (26.2%) were cytologically suspicious and unsatisfactory, respectively. No false-positive cytologies were found in the current series.
The current prospective study indicates that mammography combined with FNAC provides an accurate and practical diagnostic approach for the majority of nonpalpable lesions. Patients with unsatisfactory and false-negative lesions should undergo excisional biopsy.
由于不同放射学检查方法的特异性较低,不可触及乳腺病变的早期诊断是一项医学挑战。立体定向引导下的细针穿刺细胞学检查(FNAC)是这些病变管理中的一种辅助诊断方法。本文的主要目的是评估FNAC对不可触及乳腺病变患者的诊断准确性。
对357例(均为女性)患者的371个病变采用立体定向引导技术进行FNAC。在这些病例中,随后对238例患者的243个病变进行了手术切除活检,并构成了本研究的基础。对这些病例的细胞学和组织学诊断进行了统计分析。
组织学上,107个病变(44%)为良性,136个病变(56%)为恶性。在136个恶性病变中,细胞学诊断与之相符的有73个(53.7%),可疑的有15个(11.0%),假阴性的有12个(8.8%)(良性),不满意的有36个(26.5%)。在107个良性病变中,细胞学与组织学相符的有75个(70.1%),而细胞学可疑和不满意的分别有4个(3.7%)和28个(26.2%)。本系列中未发现假阳性细胞学诊断。
目前的前瞻性研究表明,乳腺钼靶联合FNAC为大多数不可触及病变提供了一种准确且实用的诊断方法。对不满意和假阴性病变的患者应进行切除活检。